Biggest News Aggregation in the World
๐Ÿ“ฐ Beigene News

Page 22 - Beigene News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.

BeiGene Announces Authorisation of BRUKINSA (zanubrutinib) from the United Kingdom's MHRA for the Treatment of Adults with Waldenström's Macroglobulinemia in Great Britain

Authorisation is based on Phase 3 ASPEN head-to-head trial comparing BRUKINSA against ibrutinib BeiGene (NASDAQ: BGNE; HKEX: 06160) announced today that the United Kingdom (UK) Medicines and Healthcare
United Kingdom United States Great Britain Robert Mulrooney Jane Huang Roger Owen

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

BeiGene Presents Updated Safety and Efficacy Findings on BRUKINSA (zanubrutinib) in BTK Inhibitor-Intolerant Patients with Relapsed or Refractory B-Cell Malignancies

11.12.2021 - BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today presented additional safety and efficacy results from an ongoing Phase 2 trial evaluating BRUKINSA ... Seite 1
United States Jane Huang American Society For Hematology American Society Chief Medical Officer

BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021

10.12.2021 - BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced results from the RATIONALE ... Seite 1
China National Medical Products Administration Drug Evaluation Biologics License Application

EUSA Pharma (UK), Ltd.: BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease

BeiGene, Ltd. (NASDAQ:BGNE; HKEX:06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has approved SYLVANT(siltuximab for injection) for the
United States Rebecca Kerr Gabrielle Zhou Liza Heapes Xiaobin Wu Carsten Thiel

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science